ArticleTranslational cancer research2025
High TERF2 expression is associated with poor prognosis and its suppression attenuates progression in acute myeloid leukemia.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Telomeric repeat-binding factor 2 (TERF2/TRF2), a core constituent of the shelterin complex that orchestrates telomere protection mechanisms, plays a pivotal role in preserving telomere structural integrity and maintaining genomic homeostasis. While dysregulated TERF2 expression has been implicated in tumorigenesis, its functional role and clinical relevance in acute myeloid leukemia (AML) remain poorly defined. Therefore, this study aimed to elucidate the functional role, underlying mechanisms, and clinical relevance of TERF2 in AML. Methods: TERF2 messenger RNA (mRNA) expression in peripheral blood mononuclear cells (PBMCs) from AML patients was quantified by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Transcriptomic data from The Cancer Genome Atlas (TCGA) database and Genotype-Tissue Expression (GTEx) databases were analyzed to assess TERF2's prognostic significance. The viability of AML cells was assessed using Cell Counting Kit-8 (CCK-8) assay, while cell cycle and apoptosis were analyzed via flow cytometry with propidium iodide (PI) staining and fluorescein isothiocyanate-labelled annexin V (annexin V-FITC) dual-labeling, respectively. An orthotopic xenograft model in NOD-SCID IL2rg (NSG) mice was established to monitor leukemia burden via bioluminescence imaging. Results: TERF2 was significantly overexpressed in AML patients and correlated with adverse clinicopathological features, including elevated white blood cell counts (WBCs), increased bone marrow (BM) blast percentages, and higher peripheral blood (PB) blast counts. Clinically, high TERF2 expression predicted shorter overall survival (OS). TERF2 knockdown induced apoptosis, suppressed cell proliferation, and downregulated the E2F pathway, while simultaneously enhancing cuproptosis susceptibility, as evidenced by reduced half-maximal inhibitory concentration (IC Conclusions: TERF2 is overexpressed in AML, with a marked correlation between TERF2 levels and clinicopathological features, suggesting a potential role for TERF2 in the prognosis of AML. Downregulation of TERF2 inhibits the AML cell proliferation, induces apoptosis, and modulates cuproptosis sensitivity possibly via the E2F-mediated pathway. Targeting TERF2 not only inhibits proliferation but also unlocks cuproptosis as a therapeutic vulnerability, offering a potential strategy for AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.